Form 4 for ZNTL Zentalis Pharmaceuticals, Inc.
Accepted 2023-02-01 00:00:00 ET · period of report 2023-02-01 · accession 0001725160-23-000018 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-02-01 | 2023-02-01 | ZNTL | Blackwell Kimberly | CEO, Dir | A - Grant | $0.00 | +244.8K | 249.8K | +4,896% | $0 |
| D | 2023-02-01 | 2023-02-01 | ZNTL | Blackwell Kimberly | CEO, Dir | A - Grant | $0.00 | +355.2K | 355.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-01 | A | A | 244,800 | $0.00 | 249,800 | D | — | — | (F1) Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-02-01 | A | A | 355,200 | $0.00 | 355,200 | D | $23.65 · — to 2033-01-31 | 355,200 Common Stock | (F2) The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. |